Income statement
GBP
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 0 | 0 |
| Gross Profit | 4M | 5M | 5M | -740K | -249K |
| Operating Income | -15M | -12M | -12M | -13M | -9M |
| EBITDA | -15M | -12M | -12M | -4M | -15M |
| Net Income | -12M | -12M | -12M | -2M | -15M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.2762
+0.00% today
Window Change
-24.36%
Window
May 29, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars · May 29, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scancell Holdings plc (SCNLF) is a Healthcare stock with a market cap of $160.00M and listed on OTC. The stock last traded around $0.28 and down 24.4% across the available one-year price window (May 29, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of -10.6%, EPS growth of -85.3%, a dividend yield of 0.0%. What stands out right now is revenue -10.6%, EPS -85.3%, free cash flow +59.5% with operating margin -283.3% and ROIC -113.8%. Valuation already assumes a fairly strong business story at price/sales 33.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCNLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCNLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCNLF Max Drawdown
-26.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCNLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$15.5M
-649.5% YoY
Free Cash Flow
-$4.8M
+43.9% YoY
Revenue Growth
-10.6%
EPS Growth
-85.3%
Gross Margin
78.5%
Net Margin
-117.0%
Income statement
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 0 | 0 |
| Gross Profit | 4M | 5M | 5M | -740K | -249K |
| Operating Income | -15M | -12M | -12M | -13M | -9M |
| EBITDA | -15M | -12M | -12M | -4M | -15M |
| Net Income | -12M | -12M | -12M | -2M | -15M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 15M | 20M | 41M | 41M |
| Total Assets | 23M | 24M | 30M | 49M | 9M |
| Total Liabilities | 27M | 27M | 37M | 30M | 1M |
| Shareholder Equity | -4M | -4M | -10M | 18M | 19M |
| Total Debt | 16M | 20M | 20M | 19M | 15M |
| Net Debt | -627K | 5M | -387K | -26M | -26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+38.8% YoY
Capital Expenditures
27K
+96.4% YoY
Free Cash Flow
5M
+43.9% YoY
Key ratios
Gross Margin
78.5%
Operating Margin
-283.3%
Net Margin
-117.0%
ROE
90.3%
Debt / Equity
-1.93x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.